Previous close | 1.3300 |
Open | 1.8000 |
Bid | 2.4000 |
Ask | 2.9000 |
Strike | 460.00 |
Expiry date | 2024-05-31 |
Day's range | 1.8000 - 3.3000 |
Contract range | N/A |
Volume | |
Open interest | 20 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.